FDA
-
-
-
-
-
-
-
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
-
-
-
-
-
-
-
Mesoblast acquires CAR platform technology to enhance cell therapies
-
-
-
-
-
-
-
Mesoblast to Host R&D Day on April 8, 2026
-
-
-
-
-
-
-
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
-
-
-
-
-
-
-
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
-
-
-
-
-
-
-
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
-
-
-
-
-
-
-
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
-
330,182 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

